INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
| Mar2021 | ₹3.92 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | 3.96 | |
| Mar2021 | ₹3.92 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹204.0 Cr | -3.3% | -5.1% | -31.9% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,708.7 Cr | -0.5% | -3% | -27.4% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,129.1 Cr | -6.6% | -5.8% | -7.5% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,030.5 Cr | 3.5% | NA | NA | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,010.1 Cr | 0% | 0.5% | 2.7% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹431.1 Cr | -4% | -9% | -0.9% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -3.3% |
-5.1% |
-31.9% |
| SENSEX | -0.3% |
-4.3% |
-8.9% |
You may also like the below Video Courses